WWW.6-DOMAINS.COM IS NOT INTENDED FOR US, UK OR IRELAND AUDIENCES

Moderate psoriatic arthritis: Burden of disease and unmet needs

What is moderate psoriatic arthritis?

Moderate psoriatic arthritis encompasses a variety of manifestations that contribute to disease burden.45,64—69 Patients with moderately active disease may have limited joint involvement (oligoarticular or low-range polyarticular disease)64—67, as well as any of the other key domains of psoriatic arthritis (see Figure 10)45. More than 50% of patients also have at least one comorbidity associated with psoriatic arthritis. 68 An additional characteristic of moderate psoriatic arthritis is the lack of poor prognostic factors that would indicate severe disease:70

  • No highly active disease (e.g. erosive disease, highly active enthesitis and/or dactylitis, elevated levels of inflammation markers such as ESR and CRP attributable to psoriatic arthritis, and joint deformities that interfere with function)
  • No rapidly progressive disease or long-term damage

In these patients, symptoms may be considered as not severe enough for biologics; patients with limited joint involvement are likely to have less erosive disease.69

Play button

Dr William Tillett and Professor Pascal Richette discuss the patient with moderate psoriatic arthritis and the burden of disease.

Moderate psoriatic arthritis is associated with a considerable disease burden

Patients with limited joint involvement report a significant burden of disease, comparable to polyarticular disease (see Figure 9).64,65,67,71

Despite being considered by their physicians to have reached an acceptable disease state, approximately 35% of patients have residual disease activity while being treated with conventional treatments.72 These patients do not have their treatment adjusted, despite alternatives being available.45,73

Rheumatologists need to consider the potential involvement of the different domains of psoriatic arthritis. GRAPPA recommendations indicate that the treatment goal of psoriatic arthritis should be the lowest possible disease activity across all domains of the disease.45 To achieve this treatment goal, patients should be promptly and regularly evaluated and have treatments adjusted accordingly.45

Fig. 9 Patient burden of disease is similar across PsA phenotypes

Fig. 9 Patient burden of disease is similar across PsA phenotypes

Tap to zoom zoom
Fig. 10 Presence of core domains in psoriatic arthritis

Fig. 10 Presence of core domains in psoriatic arthritis

Tap to zoom zoom

References

1. Kavanaugh A, et al. Rheumatol Ther 2016;3:91–102
2. Kyriakou A, et al. Sci World J 2014; Article ID 508178;
3. Lee E, et al. J Exp Med 2004;199:125–30;
4. Lowes M, et al. J Invest Dermatol 2008;128:1207–11
5. Yao Y, et al. PLoS One 2008;3:e2737
6. Taylan A, et al. Rheumatol Int 2012;32:2511
7. Limon-Camacho L, et al. J Rheumatol 2012;39:830–5.
8. Van Kuijk A and Tak P. Curr Rheumatol Rep 2011;13:353–9
9. Ritchlin C, et al. J Rheumatol 1998;25:1544–52
10. Menon B, et al. Arthritis Rheumatol 2014;66:1272–81
11. Celis R, et al. Arthritis Res Ther 2012;14:R93
12. Spadaro A, et al. Ann Rheum Dis 2002;6:174–6
13. Molteni S and Reali E. Psoriasis: Targets and Therapy 2012;2:55–66
14. Siegel E, et al. Curr Opin Rheumatol 2015;27:111–7
15. Lories R, et al. Nat Med 2012;18:1018–9
16. Ebihara S, et al. Autoimmunity 2015;29:1–8
17. Ruutu M, et al. Arthritis Rheum 2012;64;2211–22
18. Sherlock J, et al. Nat Med 2012;18:1069–77
19. Yamamoto M, et al. J Invest Dermatol 2015;135:445–53
20. Reinhardt A, et al. Arthritis Rheumatol 2016;68:2476–86
21. Coates LC, et al. Lancet 2015;386:2489–98.
22. Mease PJ, et al. Drugs 2014;74:423–41.
23. Schafer P. Biochem Pharmacol 2012;83:1583–90.
24. Van Kuijk A and Tak P. Curr Rheumatol Rep 2011;13:353–9
25. Ritchlin C, et al. J Rheumatol 1998;25:1544–5226. Menon B, et al. Arthritis Rheumatol 2014;66:1272–81
27. Celis R, et al. Arthritis Res Ther 2012;14:R93
28. Spadaro A, et al. Ann Rheum Dis 2002;6:174–6
29. Molteni S and Reali E. Psoriasis: Targets and Therapy 2012;2:55–66

26. Menon B, et al. Arthritis Rheumatol 2014;66:1272–81
27. Celis R, et al. Arthritis Res Ther 2012;14:R93
28. Spadaro A, et al. Ann Rheum Dis 2002;6:174–6
29. Molteni S and Reali E. Psoriasis: Targets and Therapy 2012;2:55–66
30. Siegel E, et al. Curr Opin Rheumatol 2015;27:111–7
31. Lories R, et al. Nat Med 2012;18:1018–9
32. Ebihara S, et al. Autoimmunity 2015;29:1–8
33. Ruutu M, et al. Arthritis Rheum 2012;64;2211–22
34. Sherlock J, et al. Nat Med 2012;18:1069–77
35. Yamamoto M, et al. J Invest Dermatol 2015;135:445–53.
36. Reinhardt A, et al. Arthritis Rheumatol 2016;68:2476–86
37. Taylan A, et al. Rheumatol Int 2012;32:2511
38. Limon-Camacho L,et al. J Rheumatol 2012;39:830–5.
39. Lee E, et al. J Exp Med 2004;199:125–30
40. Lowes M, et al. J Invest Dermatol 2008;128:1207–11
41. Yao Y, et al. PLoS One 2008;3:e2737
42. Kyriakou A, et al. Sci World J 2014;Article ID 508178.
43. Gottlieb A, et al. J Am Acad Dermatol 2008;58:851–64.
44. Scutellari P, et al. Eur J Radiol 1998;27(suppl 1):S31–38.
45. Coates LC, et al. Arthritis Rheumatol 2016;68:1060–71.
46. Moll JMH and Wright V. Semin Arthritis Rheum 1973;3:55–78.
47. Helliwell PS. Clin Rheum 2015;33:S44-47
48. McGonagle D, et al. Lancet 1998;352:1137–40.
49. McGonagle D & McDermott MF. PLoS Med 2006;3:e29.

60. Husted JA, et al. J Rheumatol 2013;40:1349–56.
61. Edson-Heredia E, et al. J Eur Acad Dermatol Venereol 2015;29:955–63.
62. Ogdie A, et al. J Rheumatol 2014;41:2315–22.
63. Ogdie A, et al. J Invest Dermatol 2017 [Epub]
64. Wervers K, et al. J Rheumatol 2018;45:1526–31
65. Nossent J & Gran JT. Scand J Rheumatol 2009;38:251–5
66. Coates L, et al. Arthritis Rheum 2013;65:1504–9
67. Lindqvist U, et al. J Rheum 2008;35:668–73
68. Husni M. Rheum Dis Clin N Am 2015;41:677–698
69. Queiro-Silva R, et al. Ann Rheum Dis 2003;62:68–70
70. Singh J et al. Arth care res 2019;71:5–32
71. Kavanaugh A, et al. Rheumatol Ther 2016;3:91–102
72. van Mens L, et al. Rheumatology (Oxford) 2018;57:283–90
73. van Mens L, et al. Ann Rheum Dis 2017;77:251–7
74. Huscher D, et al. ACR 2015: Abstract 679
75. Veale DJ & Fearon U. RMD Open 2015;1:e000025
77. Wilsdon TD, et al. Cochrane Database Syst Rev 2017, Art. No.: CD012722
76. Dures E, et al. Patient 2017;10:455–62
78. Xu U, et al. Am Health Drug Benefits 2018;11:408–17
79. Lebwohl M, et al. J Am Acad Dermatol 2014;70:871–81
80. van de Kerkhof P, et al. J Eur Acad Dermatol Venereol 2015;29:2001–210
81. Gossec L, et al. Ann Rheum Dis 2014;73:1012–19
82. Lubrano E, et al. Clin Exp Rheumatol
2015;33(5 Suppl 93):S51–4
83. FitzGerald O, et al. Ann Rheum Dis 2012;71:358–62
84. Waxman R & Helliwell P. Ann Rheum Dis 2018;77:467–8

Open pop-up
celgene

© Celgene Corporation 2018. All rights reserved
Six Domains Programme was developed by Celgene

logo white

We use cookies to improve the website and your navigation experience based on our Terms of Use and Privacy Policy. To accept cookies continue to browse the site or click the button. For information on how we use cookies and how to disable them, please visit our Cookies Policy.

OK